prostate

FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer

FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer

The FDA has granted accelerated designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression on an androgen receptor (AR) pathway inhibitor.1 An antibody-drug conjugate (ADC), ARX517 consists of a fully humanized prostate-specific membrane antigen (PSMA) monoclonal antibody that is bound to AS269. …

FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer Read More »

Be allowed

Meta-analysis of the addition of docetaxel to ADT in hormone-sensitive metastatic prostate cancer

By Matteo Stenger Posted: 14/07/2023 10:57:00 Last update: 07/14/2023 12:02:42 In a systematic review and single patient meta-analysis reported in The Oncological Lancet, Claire L. Vale, PhDand colleagues from the STOPCAP M1 collaboration identified factors associated and unassociated with improved outcomes after the addition of docetaxel to androgen deprivation therapy (ADT) in hormone-responsive metastatic prostate …

Meta-analysis of the addition of docetaxel to ADT in hormone-sensitive metastatic prostate cancer Read More »

Scroll to Top